The pandemic pushed major biotech stocks into the spotlight as vaccine demands rose to unprecedented highs. Investors flocked to the industry in the next few years after the COVID-19 breakout. However, interest soon waned, and the money flowed elsewhere.
While biotech may not be the flavor of the day, there are still opportunities available to investors willing to buy companies that offer the potential to revolutionize medicine and how we fight against complex diseases. A close look at some of the companies in the sector may pose another potential for investors to take advantage of these medical developments. In this article, we will look at three biotech stocks that have promising growth potential.
This post originally appeared at InvestorPlace.